Gijs van Haaften

Associate Professor

Universitair Medisch Centrum Utrecht
Country flagNetherlands
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Spinal muscular atrophy (SMA) is a severe neurodegenerative disease caused by defects in the survival motor neuron 1 ( SMN1 ) gene. The wide variability in SMA severity is partially explained by an inverse correlation with copy number variation of the second human SMN gene ( SMN2 ). Nevertheless, significant variability in severity and treatment response remains unexplained, prompting a search for accessible biomarkers that could explain and predict this variability. DNA methylation of SMN2 has been proposed as one such biomarker, but comprehensive evidence and analyses are lacking. Here, we combined long-read nanopore sequencing with targeted bisulfite sequencing to enable high-resolution analysis of SMN2 -specific methylation patterns. We observed tissue-specific variation in DNA methylation across the entire 30 kb SMN2 gene in 29 patients analyzed by long-read nanopore sequencing, identifying variable methylation patterns in the promoter, introns, and 3’ UTR. Subsequent targeted analysis of these regions by bisulfite sequencing of blood-derived DNA in 365 SMA patients showed no association between SMN2 methylation and disease severity or treatment response, excluding blood methylation patterns as predictive biomarkers. However, we discovered significant age-associated variation in SMN2 methylation, particularly in intron 1 and the 3’ UTR, highlighting DNA methylation as a possible modifier of SMN expression during development and aging. Our approach provides a broadly applicable strategy for detailed but cost-effective and high-throughput characterization of DNA methylation in other genes and diseases, including complex genetic regions.

Year:

2024

The complex 2 Mb survival motor neuron (SMN) locus on chromosome 5q13, including the spinal muscular atrophy (SMA)-causing gene SMN1 and modifier SMN2 , remains incompletely resolved due to numerous segmental duplications. Variation in SMN2 copy number, presumably influenced by SMN1 to SMN2 gene conversion, affects disease severity, though SMN2 copy number alone has insufficient prognostic value due to limited genotype-phenotype correlations. With advancements in newborn screening and SMN -targeted therapies, identifying genetic markers to predict disease progression and treatment response is crucial. Progress has thus far been limited by methodological constraints. To address this, we used targeted nanopore long-read sequencing to analyze copy-specific variation in SMN and neighboring genes. In 25 healthy controls, we identified single nucleotide variants (SNVs) specific to SMN1 and SMN2 haplotypes that could serve as gene conversion markers. In 31 SMA patients, 45% of haplotypes showed varying SMN1 to SMN2 gene conversion breakpoints, serving as direct evidence of gene conversion as a common genetic characteristic in SMA and prompting further investigation into gene conversion markers as disease modifiers. Our findings illustrate that both methodological advances and the analysis of patient samples are required to advance our understanding of complex genetic loci and address critical clinical challenges.

Year:

2024

Collaborators (4)

Ewout J. N. Groen

Associate professor

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Jan Veldink

Professor of Neurology and Neurogenetics

University Medical Center Utrecht, Utrecht University

NETHERLANDS
View details

Hanneke W. M. van Deutekom

Head of Bioinformatics

University Medical Center Groningen

NETHERLANDS
View details

Roy Straver

Senior Scientist

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details